Menu
← Oncology Approval Tracker
FDA DECISION ·
Keytruda + chemotherapy
pembrolizumab + fluoropyrimidine- and platinum-containing chemotherapy · Merck
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
First-line treatment for adults with HER2-negative gastric or gastroesophageal junction adenocarcinoma that is unresectable locally advanced or metastatic.
LAMPGEN ANALYSIS
Why it matters
The indication added pembrolizumab to a platinum and fluoropyrimidine backbone in the HER2-negative setting.
What research teams should watch
Verify HER2 testing and prior systemic treatment before choosing the gastric combination pathway.
PRIMARY RECORDS